

PROLIRA DELTASCAN

THE FIRST AND ONLY OBJECTIVE MEDICAL DEVICE FOR DELIRIUM DETECTION

混乱

Revolutionize delirium care

Delirium detection is complicated and confusing. International guidelines say and research shows that in current practice only 30 - 50% of the delirium cases are detected. Patients, caregivers, and hospitals are suffering the consequences while healthcare cost keep rising. To help healthcare professionals detect delirium, DeltaScan is created.

Currently the Gold Standard for delirium diagnosis is an expert opinion based on extensive cognitive and attention testing, working through all delirium symptoms according to the DSM-5 criteria. This takes approximately 15 minutes, hence it is costly, and not feasible for systematic monitoring of all patients who are at risk of delirium. Research demonstrates that delirium experts disagree in 21% of the cases.

In most hospitals, nurses are tasked with delirium detection every shift. The group of patients that is at risk of delirium is monitored 2 or 3 times a day with a checklist (e.g. CAM-ICU, DOSS, NuDesc). Monitoring systems based on checklists and the Gold Standard are subjective. The sensitivity is variable and appears to be related to users.

There is a clinical demand to improve delirium detection and moving away from subjective diagnoses, that miss the majority of delirium cases and often only recognize the escalated, hyperactive, type of delirium.

It is our ambition to equip nurses with the right tool to detect delirium as early as possible and in all patients. DeltaScan is an objective device that detects 85 - 90% of this medical emergency at an early stage and also recognizes the frequently occurring hypoactive (silent) type of delirium.

As delirium is acute failure of the brain, with DeltaScan, nurses can measure if patients have brain activity indicative of delirium or not. In a 3-minute process, every patient can be monitored every shift. It is nearly as simple as taking a blood pressure.

The next vital sign



Delirium is progressively portrayed as the next vital sign.

Vital signs are clinical measurements that indicate the state of a patient's essential body functions, specifically pulse rate, temperature, respiratory rate and blood pressure. Delirium provides a vital sign for the brain, and the mental state of the patient.

Prolira's proprietary technology to monitor acute brain failure, is based on measuring a biomarker in brain activity (via electroencephalography, EEG). Through algorithms based on world class clinical expertise and research, smart artefact removal technologies and unique device design, this new vital sign monitor can be used effectively by nurses at the patient's bedside.

360° benefits



Prolira's DeltaScan will improve the quality of care and patient safety. Improved delirium detection improves patient outcome and reduces hospital length of stay, while reducing healthcare costs. It's beneficial for patients, their families, healthcare professionals and budget holders.

Improve quality of care



Medical guidelines prescribe patients at risk of delirium to be monitored at least every shift. The use of DeltaScan 3 times a day for every patient at risk, improves compliance. It makes documentation and communication about results effective and practical.

Academic network and innovation



The innovation is based on clinical experience and land mark research of the University Medical Center Utrecht, the Netherlands, led by neurologist-intensivist Prof. Dr. Slooter. An international clinical evaluation board consisting of 3 leading academic medical centers in is formed. Prolira is a spin off of the University Medical Center Utrecht.

INVESTMENT IN CARE THAT MATTERS



Planning

In the first half of 2018, DeltaScan Version 1 will be CE marked and introduced in the clinic for multiple fast clinical investigations, gathering more proof of validity and usefulness in the clinical setting.



In the second half of 2018, the first DeltaScans will be available for routine clinical use. Hospital departments that can't wait to improve delirium detection are invited to contact Prolira.



Starting in the second half of 2018, a large scale international multicenter clinical evaluation in ICU's and on General Wards (Cardiothoracic surgery, Geriatric Traumatology, Internal Medicine) is being prepared, to evaluate the delirium detection rate, the timeliness of detection and the length of stay, before and after implementation of DeltaScan.

This study is led by our Clinical Evaluation Board, consisting of Prof Dr Arjen Slooter, Intensive Care Neuropsychiatry, UMC Utrecht, the Netherlands; Prof Dr mr Bas de Mol, vice-president of the Amsterdam Medical Center AMC Heartcenter the Netherlands and Prof Dr Claudia Spies, Head of the Intensive Care of Charité Berlin, Germany.



Contact

www.prolira.com
Prolira BV
Padualaan 8
3584 CH Utrecht
the Netherlands
Annemarie Willems | a.willems@prolira.com | +31 6 2297 8972



YOUR NEXT VITAL SIGN MONITOR for early and objective delirium detection

DeltaScan Monitor

DeltaScan Patch (single use)

